Clinical trials: Bone Marrow Diseases
Myelodysplastic Syndromes
Nivolumab With Chemotherapy in Refractory MDS
There is evidence of involvement of checkpoint pathways, including PD-1, in the pathogenesis and resistance of myelodysplastic syndrome (MDS).
- Trial name
- NCT03259516
- Testing
- Nivolumab, Azacitidine, Fludarabine
- Where
- Russia
- Volunteers
- 2 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center
Cervical Spondylotic Myelopathy, Ossification of Posterior Longitudinal Ligament in Cervical Region
The Application of Enhanced Recovery After Surgery Clinical Pathway in Posterior Cervical Spine Surgery
This study intends to establish a multidisciplinary collaborative ERAS clinical pathway of cervical posterior surgery,and to verify its effectiveness, safety and value in health economics.
- Trial name
- NCT05149404
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Peking University Third Hospital
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Bone Marrow Transplantation, Graft vs Host Disease
Toward Immune Biomarkers for Tolerance and GvHD in Humans
Graft-versus-Host Disease (GVHD), is the most frequent and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Bone Marrow Transplantation, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
- Trial name
- BioGvHD (NCT02319226)
- Testing
- Transplantation from an HLA-identical sibling donor
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Severe Combined Immunodeficiency
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID
Severe combined immune deficiency (SCID) may result from inherited deficiency of the enzyme adenosine deaminase (ADA). Children with ADA-deficient SCID often die from infections in infancy, unless treated with either a bone…
- Trial name
- NCT00794508
- Testing
- ADA gene transfer
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Donald B. Kohn, M.D.
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Immune System Diseases, Autoimmune Diseases
Clonal Hematopoiesis of Immunological Significance
Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic)…
- Conditions
- Immune System Diseases, Autoimmune Diseases, Inflammation, Autoinflammatory Diseases
- Trial name
- CHIS (NCT05969821)
- Testing
- observational cohort study
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
This is the study to test combination regimen of Nilotinib and Ruxolitinib therapy for the treatment of patients with Philadelphia positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who is resistant to…
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT01914484
- Testing
- Nilotinib, Ruxolitinib
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Hematologic Malignancy
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
- Trial name
- NCT02352558
- Testing
- BBI608, Dexamethasone, Bortezomib
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma America, Inc.
Myelodysplastic Syndromes
CyFluATG in Lower Risk MDS
To evaluate the efficacy of the conditioning regimen with cyclophosphamide, fludarabine, and antithymocyte globulin (CyFluATG) for allogeneic hematopoietic cell transplantation (HCT) in patients with lower risk myelodysplastic…
- Trial name
- NCT06098326
- Testing
- cyclophosphamide, fludarabine, and antithymocyte globulin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Iron Overload
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
The study is designed to collect safety and efficacy of Desferasirox in Chinese patients with Iron Overload and Aplastic Anemia.
- Trial name
- NCT01546415
- Testing
- Desferasirox
- Where
- 7 sites in China
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Acute Lymphocytic Leukemia (ALL)
Expanded Access to Navitoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
- Trial name
- NCT03592576
- Testing
- Navitoclax, Venetoclax
- Sponsor
- AbbVie
Leukemia, Myelodysplastic Syndromes
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with myelodysplastic…
- Trial name
- NCT00003171
- Testing
- bryostatin 1
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Myeloid, Chronic
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- Trial name
- NCT00538109
- Testing
- Glivec®/Gleevec®
- Volunteers
- 8 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Myelodysplastic Syndrome, Anemia in Myelodysplastic Syndromes
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
This research is being conducted to asses if HT-6184 is effective in the treatment of Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia.
- Trial name
- NCT07052006
- Testing
- HT-6184
- Where
- 10 sites in India
- Volunteers
- 37 people
- Sponsor
- Halia Therapeutics, Inc.
Myelofibrosis (MF)
Momelotinib Effectiveness in Myelofibrosis
Observational study aimed at evaluating the use of momelotinib in patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) in a real-world setting.
- Trial name
- NCT07249606
- Volunteers
- 93 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Polycythemia Vera, Essential Thrombocythemia
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
The purpose of this project is to find genes whose mutations cause Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis.
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Trial name
- NCT00715247
- Where
- United States
- Volunteers
- 726 people, healthy volunteers welcome
- Sponsor
- University of Utah
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation
This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.
- Trial name
- NCT00795548
- Testing
- 5-Azacitidine
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
The Registry MDS is an ongoing, observational study that has collected longitudinal data on diagnostics, demographics, clinical parameters, and health Care Interventions (HCI) from patients with MDS and therapy-related acute…
- Trial name
- NCT06956755
- Where
- France
- Volunteers
- 6,990 people
- Sponsor
- Groupe Francophone des Myelodysplasies